Cevallos, CintiaCulasso, Andrés C. A.Urquiza, JavierOjeda, DiegoSued, OmarFigueroa, María I.Avila, María M.Delpino, M. VictoriaQuarleri, Jorge F.2024-05-212024-05-212020-9Arch Virol . 2020 Dec;165(12):2915-2919. doi: 10.1007/s00705-020-04823-z. Epub 2020 Sep 25.https://repositorio.huesped.org.ar/handle/123456789/1002Human immunodeficiency virus type 1 (HIV) primary drug resistance mutations (DRMs) influence the long-term therapeutic effects of antiretroviral treatment (ART). Drug-resistance genotyping based on polymerase gene sequences obtained by next-generation sequencing (NGS) was performed using samples from 10 ART-naïve HIV-infected men who have sex with men (MSM; P1-P10) from the acute/early to chronic stage of infection. Three of the 10 subjects exhibited the presence of major (abundance, ≥ 20%) viral populations carrying DRM at early/acute stage that later, at the chronic stage, dropped drastically (V106M) or remained highly abundant (E138A). Four individuals exhibited additional DRMs (M46I/L; I47A; I54M, L100V) as HIV minority populations (abundance, 2-20%) that emerged during the chronic stage but ephemerally.HIVantiretroviral treatmentIn vivo drug resistance mutation dynamics from the early to chronic stage of infection in antiretroviral‑therapy‑naïve HIV‑infected men who have sex with men